Superworth

Latigo Biotherapeutics LTGO

Drug Manufacturers - General, Healthcare
$15.02
−9.35%
Market cap
n/a
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
not a meaningful number
EV/EBIT
n/m
not a meaningful number
Revenue, 12 months
n/m
not a meaningful number
Net margin
n/m
not a meaningful number
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for LTGO, by quarter
Income statementQ1 FY25Q2 FY25Q1 FY26Q2 FY26
R&D$18.7M$22.9M$17.6M$21.2M
SG&A$2.8M$2.8M$5.8M$4.6M
−$21.5M−$25.7M−$23.4M−$25.8M
Interest expensen/a$0$0$251K
Net income−$21M−$25.8M−$23M−$25.8M
−$29.62−$36.52−$25.26−$27.59
707.5K707.5K908.9K935K

R&D: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

SG&A: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Operating income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Interest expense: Q1 FY26: 6 months less the 3 months printed beside them.

Net income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

EPS, diluted: Q1 FY25 and Q1 FY26: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY25 and Q1 FY26: share-days: the 6-month average less the second quarter's.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

More on Latigo Biotherapeutics

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .